The Relationship Between Older Adults' Knowledge of Their Drug Coverage and Medication Cost Problems by Piette, John D. & Heisler, Michele M.
BRIEF REPORTS
The Relationship Between Older Adults’ Knowledge of
Their Drug Coverage and Medication Cost Problems
John D. Piette, PhD, and Michele Heisler, MD, MPA
(See editorial comments by Dr. Richard Stefanacci on pp 166–168)
OBJECTIVES: To determine whether chronically ill pa-
tients have gaps in knowledge about their prescription drug
coverage and establish the relationship between gaps and
medication cost problems.
DESIGN: Nationwide, cross-sectional survey.
SETTING: Nationwide survey conducted via the Internet.
PARTICIPANTS: Three thousand one hundred nineteen
adults aged 50 and older (1,400 of whom were aged 65)
who had prescription drug coverage and at least one chron-
ic illness.
MEASUREMENTS: Patients were asked about features
of their drug benefits and whether they had experienced
problems due to medication costs in the prior year.
RESULTS: Twenty-five percent of respondents reported
not knowing their usual prescription copayments, and 41%
did not know whether there were caps on their drug cov-
erage. Nonwhite race and lower income were independent
risk factors for lack of knowledge about these aspects of
pharmacy benefits. Lack of knowledge regarding the limits
of coverage was associated with a greater likelihood of
cutting back on medication use because of cost pressures,
forgoing basic needs because of medication costs, borrow-
ing money to pay for prescriptions, and worrying about
medication costs (all Po.05).
CONCLUSION: Many older adults with prescription drug
coverage do not know important features of their pharmacy
benefits. Racial minorities and those with low incomes may
have the greatest difficulty understanding coverage and as a
result may be at greatest risk for underusing their benefits.
Education about Medicare reforms and other efforts to
increase prescription coverage should accompany these
policies. J Am Geriatr Soc 54:91–96, 2006.
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Out-of-pocket medication costs and the structure ofpatients’ prescription drug benefits significantly influ-
ence medication adherence1–3 and health outcomes.4–6 As a
consequence, adequate prescription medication coverage is
critical for older adults with chronic medical problems. The
planned Medicare prescription drug benefit thus represents
an important effort to address older adults’ problems due to
medication cost pressures.7
To be effective, a prescription drug policy must define a
package of benefits that enhances patients’ access to needed
drugs, minimizes inappropriate drug use, and is financially
viable for the payer. To address these potentially conflicting
requirements, most prescription drug plans are complex and
include various limits on coverage, such as copayments,
payment caps, and incentives to use lower-cost alternatives
(e.g., generics). Studies of primarily younger8–10 and older
adults11,12 suggest that many individuals have only a min-
imal understanding of their health insurance benefits.
Prescription drug benefits may be especially difficult to com-
prehend, and the planned Medicare prescription drug benefit
has been widely criticized because of its complexity.13–15
Little is known about whether older adults with pre-
scription coverage understand the policies they currently
have or how gaps in patients’ knowledge of their pharmacy
benefits influence their responses to cost pressures. Accord-
ingly, in a nationwide sample of older adults with pres-
cription drug coverage, the current study examined the
prevalence of and risk factors for gaps in patients’ under-
standing of their prescription drug costs and benefits and
the association between gaps in understanding pharmacy
benefits and medication cost problems, including nonad-
herence, cutting back on basic needs, and borrowing money
to pay for prescription drugs.
METHODS
Participants
Institutional review boards at Stanford University and the
Department of Veterans Affairs (VA) Ann Arbor Healthcare
System approved the study protocol. The study was based
on surveys completed over the Internet by a nationwide
panel of older adults living in the United States. Details
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about the panel’s recruitment and representativeness have
been reported previously, along with prevalence estimates
of problems due to medication costs such as cost-related
nonadherence and forgoing basic needs due to cost pres-
sures.1,16 All 5,644 panel members aged 50 and older who
reported taking prescription medication for diabetes mell-
itus, depression, heart problems, hypertension, or high cho-
lesterol were identified. A total of 4,264 people (76%)
completed the on-line informed consent and questionnaire.
Respondents were more likely than nonrespondents to be
white (88% vs 81%, Po.001), older (mean age 65 vs 63,
Po.001), and to have some college education (66% vs
60%, Po.001). Respondents and nonrespondents were
similar with regard to sex (P 5.29), home ownership
(P 5.44), marital status (P 5.16), and income (P 5.41). A
total of 3,291 respondents were identified for the current
study, because they answered positively to the question, ‘‘Do
you have any health insurance that helps pay for prescrip-
tion medications?’’ Of these, 151 respondents were exclud-
ed, because they reported that they did not have any medical
insurance (and therefore may have reported prescription
drug coverage in error) and 21 because of missing data on
income. The final sample included 3,119 older adults.
Survey Items
Gaps in Knowledge About Drug Copayments and
Coverage
Surveys included no instructions encouraging or prohibit-
ing respondents from identifying information about their
drug coverage from their insurance card or other available
descriptions of their policies. Patients were considered to
have a gap in their understanding of their usual cost per
prescription if they responded ‘‘I don’t know’’ to either of
the following questions: ‘‘About how much do you usually
pay out of pocket (money that isn’t reimbursed later) when
you get a brand name prescription medication?’’ or ‘‘About
how much do you usually pay out of pocket (money that
isn’t reimbursed later) when you get a generic medication?’’
Participants were coded as having a gap in knowledge about
their drug coverage’s spending limits if they responded ‘‘I
don’t know’’ to either of the following questions: ‘‘Some
health insurance plans stop paying for medication after you
reach a certain amount. Does your insurance have a limit on
the total cost of medication that it will pay for?’’ or ‘‘Some
health insurance plans have a limit on the number of dif-
ferent medications they will pay for each month. Does your
health insurance plan limit the number of medications it
will pay for?’’ Limits on the number of medications covered
have been noted as a problem with some Medicaid pre-
scription drug plans.17–19
Medication Cost Problems and Covariates
Respondents were coded as having cost-related adherence
problems if they reported medication underuse due to cost
in the prior year for prescription drugs treating any of 16
common chronic illnesses. Respondents also were asked
about other potential problems due to medication costs,
including spending less on basic needs such as food or heat
to pay medication costs, borrowing money from family or
friends to pay medication costs, and worrying about how to
pay for medications at least once per month. The wording
of these items is provided in footnotes to Table 3. Potential
covariates included measures of patients’ sociodemographic
characteristics (race, sex, educational attainment, age),
clinical characteristics (number of diagnoses, number of
prescription drugs), and relevant financial characteristics
(income, type of health insurance coverage, total monthly
out-of-pocket medication costs). Household income was
assessed via a survey item asking patients to report their
total household income within specified categories. For
health insurance, patients were categorized into the follow-
ing hierarchical groups: VA health care, Medicaid (without
VA care), Medicare (without VA or Medicaid), and private
insurance (only).
Statistical Analyses
Initial bivariate analyses examined differences across pa-
tient subgroups in the proportion of patients reporting gaps
in knowledge about their medication copayments and cov-
erage limits. Multivariate logistic regression models were
then constructed to identify the independent association
between each patient characteristic and each of these two
knowledge gaps.
In the second phase of the analysis, logistic models were
fit to assess the extent to which patients’ lack of knowledge
about these two aspects of their drug coverage was inde-
pendently associated with their likelihood of reporting
problems due to medication cost. Each logistic model con-
trolled for potential confounding by patients’ sociodemo-
graphic characteristics, number of medications, total
monthly medication costs, and insurance type. Because
these issues are particularly salient for potential beneficiar-
ies of the Medicare prescription drug benefit, analyses ad-
dressed each research question in the overall sample and
separately for the 1,400 respondents who were aged 65 and
older. To correct for the multiple comparisons across the
two samples, Po.025 (i.e., .05  2) was considered statis-
tically significant. No corrections were made for the mul-
tiple other associations tested within or across Tables 1 and
2. Auxiliary analyses examined variation in the association
between knowledge gaps and medication cost problems
across strata defined by covariates and tested for interac-
tions between knowledge gaps and respondents’ income.
No evidence of interactions between the potential risk
factors for medication cost problems was identified.
RESULTS
Patient Description
In the overall sample, 88% of respondents were white, 51%
were men, and 32% had at most a high school education. A
total of 45% were aged 65 and older, and a wide income
range was represented, with 40% of the sample reporting
annual household incomes of less than $40,000. Nearly two
thirds (64%) of the sample reported having private medical
insurance, with 8% on Medicaid alone, 7% on Medicare
alone, and 6% receiving care only at the VA. Seventy-four
percent were taking at least three prescription medications,
and 47% reported monthly out-of-pocket medication costs
of greater than $50. Patients who were aged 65 and older
were similar demographically to the overall sample,
although only 24% had annual household incomes of
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$60,000 or more, compared with 34% of respondents in
the overall sample.
Knowledge Gaps About Medication Costs and Coverage
Limits
Twenty-five percent of respondents in the overall sample
and 29% of those aged 65 and older reported not knowing
their usual out-of-pocket prescription drug copayments
(Table 1). In bivariate analyses, respondents were more
likely to lack knowledge about their usual cost per pre-
scription if they were nonwhite, had less education, were
older, or had lower incomes (all Po.025). Patients with VA
coverage, Medicaid, or Medicare were more likely to report
that they did not know their usual prescription copayments
than those with private health insurance. Respondents with
higher total monthly out-of-pocket medication costs were
more likely to report not knowing their usual copayment
per prescription than those with lower total medication
costs. For patients aged 65 and older, female sex, more
medications, and higher total monthly out-of-pocket med-
ication costs were associated with gaps in knowledge about
medication copayments (all P.001).
Forty-one percent of all respondents and 38% of those
aged 65 and older had a gap in knowledge about whether
there were limits on the number of medications or total
medication costs that their prescription plans would cover.
Nonwhites, those with less education, those who were
younger, and those with lower incomes were more likely to
report not knowing about benefit caps (all P.003). Of
respondents aged 65 and older, nonwhites and those with
lower incomes were more likely to report that they did
know whether their insurance plan had benefit caps (both
P.003).
In the overall sample, nonwhite race was independently
associated with a significant increase in respondents’ odds
of having a gap in knowledge about their usual copayments
(Table 2). Lower educational attainment, low income,
Table 1. Proportion of Respondents with Gaps in Knowledge About the Characteristics of Their Prescription Drug Benefits
Respondent Characteristic
Gap in Knowledge About Usual
Copayments Gap in Knowledge About Spending Limits
All % P-value 65 % P-value All % P-value 65 % P-value
Total 25 29 41 38
Race .01 .41 .002 .003
White 24 28 40 37
Nonwhite 30 32 49 51
Sex .10 .01 .14 .29
Male 23 26 40 37
Female 26 33 42 39
Education .001 .20 .006 .13
High school 28 31 44 40
Some college 25 29 42 39
College 20 26 37 34
Age o.001 .003
50–54 20 F 45 F
55–64 23 F 43 F
65 26 F 38 F
Income, $ o.001 .17 o.001 .002
60,000 20 25 37 33
40,000–59,999 23 28 39 34
20,000–39,999 26 29 43 39
o20,000 34 34 51 48
Medications, n .06 .001 .14 .41
1–2 22 22 41 35
3–6 25 29 42 39
7 27 35 38 39
Insurance o.001 .55 .33 .20
Department of Veterans Affairs 30 30 46 40
Medicaid 37 33 43 40
Private 22 28 40 39
Medicare 31 30 43 43
Monthly out-of-pocket cost, $ o.001 o.001 .40 .53
1–50 22 23 40 37
51–99 25 30 43 39
100 30 42 42 40
Note: To correct for the multiple comparisons across the two samples, Po.025 (i.e., .05  2) were considered statistically significant.
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Medicaid coverage, and high out-of-pocket costs were each
independent risk factors for gaps in knowledge about co-
payments. In the subgroup of respondents aged 65 and
older, a larger number of prescriptions and high out-of-
pocket costs were the only risk factors independently asso-
ciated with this knowledge gap.
In the overall sample, nonwhite race and lower income
were also independent risk factors for a gap in knowledge
about spending caps on coverage; respondents who were
older and using more medications were less likely to report
gaps in knowledge about spending caps. In the subgroup
aged 65 and older, nonwhites had nearly twice the adjusted
odds of having a gap in knowledge about spending limits as
their white counterparts (P 5.005). Similarly, those with
incomes less than $20,000 had significantly greater odds of
having this knowledge gap than those with incomes of
$60,000 or more (P 5.01).
The Association Between Gaps in Knowledge and
Medication Cost Problems
In the overall sample, 14% of respondents reported cutting
back on prescription medication use because of cost, 15%
reported forgoing basic needs because of medication cost
pressures, 5% reported borrowing money from family or
friends to pay medication costs, 8% reported increasing
their credit card debt to pay these costs, and 16% reported
worrying about medication costs at least once per month.
Ten percent of respondents aged 65 and older reported
cutting back on prescription medication use because of cost,
11% reported forgoing basic needs because of medication
cost pressures, 2% reported borrowing money from family
or friends to pay medication costs, 6% reported increasing
their credit card debt to pay these costs, and 13% reported
worrying about medication costs at least once per month.
In the overall sample and among respondents aged 65
and older, lack of knowledge about usual out-of-pocket
costs for prescription medication was not associated with
cost-related underuse or other medication cost problems
(Table 3), but respondents who reported not knowing their
drug plan’s spending limits were at significantly greater risk
for each of the five medication cost problems.
DISCUSSION
In an effort to optimize medication coverage while mini-
mizing overall insurance costs, many prescription drug
policies include features designed to increase cost sensitivity
of patients and their physicians. Unfortunately, these limits
on coverage often complicate policies in ways that may be
difficult for beneficiaries to understand. In the current study,
a large proportion of older adults with prescription drug
benefits had gaps in their knowledge about their medication
copayments and the limits on their insurance coverage.
Socioeconomically vulnerable respondents were the
most likely to have gaps in knowledge about their prescrip-
tion drug coverage. In the group aged 65 and older, racial
minority respondents and those with low incomes were
Table 2. Adjusted Odds Ratios for the Association Between Patient Characteristics and Gaps in Knowledge About
Prescription Drug Coverage
Patient Characteristic
Gap in Knowledge About
Usual Copayment
Gap in Knowledge About
Spending Limits
All 65 All 65
Nonwhite 1.4 1.1 1.3 1.8w
Female 1.1 1.3 1.1 1.0
Education (ref college)
Some college 1.2 1.0 1.2 1.2
High school 1.4w 1.2 1.2 1.2
Age (ref 50–54)
55–64 1.0 F 0.9 F
65 1.4w F 0.7z F
Income, $ (ref 60,000)
40,000–59,999 1.1 1.1 1.1 1.0
20,000–39,999 1.1 1.0 1.3w 1.2
o20,000 1.4w 1.2 1.8z 1.7w
Medications (ref 1–2)
3–6 1.1 1.3 1.0 1.1
7 1.0 1.5 0.7w 1.1
Insurance (ref private)
VA 1.4 1.2 1.1 1.1
Medicaid 1.7z 1.3 1.3 1.0
Medicare 1.2 1.1 1.0 1.2
Monthly out-of-pocket cost, $ (ref 1–50)
51–99 1.2 1.3 1.2 1.1
100 1.6z 2.2 1.1 1.1
Po  .025, w .01, z .001; to correct for the multiple comparisons across the two samples, Po.025 (i.e., .05  2) was considered statistically significant.
ref 5 reference.
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substantially more likely than other respondents to have a
gap in knowledge about their medication benefit’s spending
limits. Spending caps associated with the planned Medicare
drug policy have been highlighted as particularly confusing;
copayments for beneficiaries with incomes above 150% of
the federal poverty level will increase to 100% after their
annual drug costs exceed $2,250, until they reach $5,100
(the ‘‘doughnut hole’’), and then decrease to 5%.13 Based on
findings from the current study, it is possible that a signif-
icant number of beneficiaries may not understand those
limitsFeven if they are able to track their own accumulat-
ing drug expenditures over time.
The large proportion of older adults reporting gaps in
knowledge about their drug coverage spending limits is
particularly troubling, because respondents with these gaps
were more likely to also report problems due to medication
costs. Patients who were unaware of limits on their drug
coverage were more likely to forgo medication because of
cost pressures, to forgo basic needs because of medication
costs, to borrow money to pay for their prescriptions, and
to worry about paying for their drugs. This pattern of ef-
fects is consistent with those found in a previous study.12 In
that study, patients’ perception of their emergency depart-
ment copayment was a stronger predictor of emergency
department use than their actual copayment level, and those
who anticipated a larger copayment were at risk for avoid-
ing or delaying emergency care. The current study’s findings
raise similar concerns that some older adults may underuse
their drug benefits, because they do not understandFand
underestimateFthe ways in which their drug plan could
reduce the financial strain of their drug costs.
Clinicians, health systems, and public health organiza-
tions may be able to partially address patients’ medication
cost problems by educating patients about the benefits they
have. Unfortunately, recent studies suggest that patients do
not discuss medication cost problems with their physi-
cians,20 that clinicians fail to identify patients facing prob-
lems,21,22 and that clinicians report significant barriers to
assisting patients struggling with out-of-pocket costs.23
Many physicians are unaware of the cost of common pre-
scriptions and are therefore unlikely to take costs into ac-
count when prescribing.24 Moreover, many physicians’
primary strategy to minimize patients’ medication costs is
to give free samples. Because usually only expensive, newer
medications are available as free samples, this strategy (al-
though often appreciated by patients) can lead to increased
costs for patients over the longer term.20,25 Multifaceted
interventions addressing provider barriers to cost-effective
prescribing and patient barriers to appropriate use of avail-
able pharmacy benefits may be required to fully address
patients’ medication cost problems. As part of this effort, it
will be critical to develop effective campaigns to educate
older adults about the planned Medicare drug policy. These
initiatives may be particularly important for older adults
at highest risk for gaps in knowledge and for significant
burdens from their out-of-pocket medication costs: people
of color, those with low incomes, and those on multiple
medications.
It is not clear why the two measures of patients’ un-
derstanding of their drug coverage differed with respect to
the relationship with medication cost problems. It may be
that patients’ concerns about exceeding their (unknown)
coverage limits lead them to underuse their benefits. In
contrast, lack of information about usual copayments may
reflect patients’ overall understanding of their resources but
without the accompanied concern about impending cata-
strophic costs that exceeding a limit could signify. Future
research will be important to understand the ways in which
these two dimensions of patients’ knowledge of their cov-
erage (as well as understanding of other dimensions of their
insurance) affect their decision-making about medication
adherence and other responses to medication costs.
This study has several limitations. First, the analyses
may underestimate the proportion of older adults with
problems understanding their drug coverage, because re-
spondents who reported that they did not have pharmacy
benefits were excluded. Some of those respondents may
have had drug benefits of which they were unaware. Re-
spondents were classified as having a gap in their knowledge
about copayments and spending caps only if they explicitly
reported that they did not know; other respondents who
provided estimates may have reported erroneous informa-
tion. Also, the survey was conducted over the Internet, and
older adults who did not respond because of discomfort












Adjusted Odds Ratio (95% Confidence Interval)
About usual copayments
All respondents 1.0 (0.8–1.3) 1.1 (0.9–1.4) 1.0 (0.7–1.6) 0.8 (0.6–1.1) 1.1 (0.9–1.4)
Aged 65 1.3 (0.9–1.9) 1.3 (0.9–1.9) 0.5 (0.2–1.2) 0.8 (0.5–1.4) 1.4 (1.0–1.9)
About spending limits
All respondents 1.7 (1.4–2.1)# 1.9 (1.5–2.4)# 2.0 (1.4–2.9)# 1.4 (1.1–1.9)k 1.7 (1.3–2.0)#
Aged 65 1.6 (1.1–2.3)z 2.2 (1.5–3.2)# 2.5 (1.1–5.9)k 1.4 (0.9–2.4) 1.7 (1.2–2.4)z
Note: Each logistic regression model controlled for patients’ sociodemographic characteristics (race, sex, educational attainment, and income), number of prescription
medications, total monthly out-of-pocket drug costs, and insurance type.
 ‘‘In the past 12 months, did you ever spend less on food, heat, or other basic needs so that you would have enough money to pay for your prescription medications?’’
w ‘‘In the past 12 months, did you ever borrow money from a family member or friend to pay for your prescription medications?’’
z ‘‘In the past 12 months, did you ever increase the amount of credit card debt you carried from month to month because of the cost of your prescription medications?’’
§ ‘‘In the past 12 months, how often did you worry about paying for your prescription medications?’’
Po k .025, z .01, # .001. To correct for the multiple comparisons across the two samples, Po.025 (i.e., .05  2) was considered statistically significant.
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using computers may also have been more likely to have
problems understanding their prescription drug coverage.
Unmeasured patient characteristics, such as health literacy
or non-cost-related adherence problems, may account for
some of the relationship between patients’ understanding of
their drug coverage and their likelihood of experiencing
problems due to medication costs. Although prior studies
have linked cost-related medication underuse with adverse
health outcomes,4,5 the current study included no informa-
tion about adverse outcomes associated with patients’ gaps
in knowledge about their prescription coverage.
Patients may be more likely to know the limits of their
drug coverage when they are nearing those thresholds or
have already exceeded the limits on their benefits. Unfor-
tunately, the current study included no information about
the details of patients’ history of medication costs or their
insurance policies. If knowledge about drug coverage is a
proxy for less-generous benefits, rather than an independent
determinant of patients’ behavior, it would be expected that
reported knowledge (rather than knowledge gaps) would be
a risk factor for the medication cost problems described in
Table 3. Future studies using samples of patients with
clearly similar drug coverage would shed light on whether
reporting biases in the current study affected estimates of
the associations between drug coverage knowledge gaps
and medication cost problems.
In conclusion, the current study found that many
chronically ill older patients with prescription drug cover-
age have gaps in knowledge about their current medication
costs and benefits. Socioeconomically vulnerable patients
are especially at risk. Patients who report problems under-
standing their prescription coverage are more likely to cut
back on medication use and to experience other problems
because of cost pressures. In light of the complexity of the
planned Medicare prescription drug program, government
agencies and other organizations should make intensive ef-
forts to educate Medicare recipients and enable them to
take full advantage of the new benefits.
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